

s22

From: s47F@unisa.edu.au>
Sent: Monday, 22 June 2015 4:16 PM
To: s22
Subject: RE: bDMARDs and infection project [SEC=UNCLASSIFIED]

Hi s22 I have sent through invoice request to our finance area, so hopefully this will come through to you very soon.

Kind Regards

s47F

From: s22@health.gov.au]
Sent: Monday, 22 June 2015 3:09 PM
To: s47F
Subject: RE: bDMARDs and infection project [SEC=UNCLASSIFIED]

Hi s47F

The Department of Health ABN is **83 605 426 759**

My finance officer has advised that the invoice needs to be dated and received in this financial year. Happy for you to email it to me directly.

Many thanks

s22

Assistant Director
 Drug Utilisation | Pharmaceutical Evaluation
 Department of Health
 Ph: (02) 6289 s22
 GPO Box 9848, Canberra ACT 2601
 Sirius building, Woden | s22

From: s47F@unisa.edu.au]
Sent: Monday, 22 June 2015 2:33 PM
To: s22
Subject: FW: bDMARDs and infection project [SEC=UNCLASSIFIED]

Hi s22, s47F has asked me follow up on submission of invoice to you, can you please confirm Department of Health ABN number.

Kind Regards

s47F

Project Administration Coordinator
 Veterans' MATES Project
 Quality Use of Medicines and Pharmacy Research Centre
 Sansom Institute
 University of South Australia
 Ph s47F
 Mobile s47F
 Fax s47F

From: s22 [redacted] @health.gov.au] **On Behalf Of** dusc
Sent: Thursday, 18 June 2015 5:28 PM
To: s47F [redacted]
Cc: s22 [redacted]
Subject: RE: bDMARDs and infection project [SEC=UNCLASSIFIED]

Hi s47F [redacted]

As the report for the bDMARDs with infection project has been provided to the department and was presented at DUSC, could you please send me an invoice for \$27,500 (GST inclusive) in relation to this project.

Many thanks

s22 [redacted]

Assistant Director
Drug Utilisation | Pharmaceutical Evaluation
Department of Health
Ph: (02) 6289 s22 [redacted]
GPO Box 9848, Canberra ACT 2601
Sirius building, Woden | s22 [redacted]

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH AND AGED CARE



Australian Government

Department of Health

**Claim for Payment
WITH a Purchase Order**

FOI 4981 Document 2

DOCUMENT NUMBER (FSC use only)

Sections 1 – 4 are mandatory and must be completed.

Failure to complete may result in payment not being made and paperwork returned to Division for completion.

1. Funds and SourceCompany
Code **1000**Amount
(including GST) **27,500****2. Supplier Details**Vendor
Name **University of South Australia**SAP Vendor
Number **100774****3. Good / Services Received**Receiving
Officer **s22**Signature **s47F** **22 / 6 / 15**Date Services/Goods Received **28 / 05 / 15**Date Invoice Received in Dept **22 / 06 / 15****4. Payment Instructions**Division Contact
(if different to above)Phone **s22**Purchase
Order **4500116783**Line
Item **1**Goods
ReceiptPayment Terms 1 ☐ 7 ☐ 14 ☐ 28 ☒ xOverseas ☐ Collect cheque ☐**5. Additional Payment Instructions (complete if applicable)**RCTI ☐ RCTI to
be sent toRCTI
TextCross
Company ☐ From

To

If you require assistance in completing this form, contact your BMU/FLO in the first instance or Accounts Payable on x5556.
When this form has been completed, attach invoice & supporting documentation and forward to AP CSC - MDP 356.

For Financial Services Centre Use ONLY

SAP/Invoice match		Correctly Rendered Tax Invoice Attached		
Bank Details		Less than \$1000	More than \$1000	Exception Reasons
ABN		Words Tax Invoice	Extra requirements	No GST Charged
GST		Supplier Name	Recipient eg DOHA, NICNAS, NHMRC	Less than \$82.50
Checked by		Supplier ABN	Address or ABN of recipient	Withholding Applied
		Description of Goods		ATO Supplier Statement provided to Vendors
		Date of Issue		

Additional information – including details if invoice unable to be processed.



University of
South Australia

Finance Unit
GPO Box 2471
Adelaide SA 5001

ABN 37 191 313 308

TAX INVOICE

DEPT OF HEALTH & AGEING
ATTN: s22
GPO BOX 9848
CANBERRA ACT 2601

Invoice No:	128263
Date:	22/06/2015
Debtor Code:	DEPHEA00
Your Ref.	
Your ABN:	83 605 426 759

Please direct initial enquiries to: **s22**

Description		Exclusive GST	GST	Inclsv Amt
Work Order (WO:37) 7/4/2015				
Work Undertaken for Dept of Health				
As Per W/O Dept of Veterans Affairs				
Determine rate of Infections-bDMARDs		25,000.00	2,500.00	27,500.00
Terms: Net	14 days	Total Amount Due:	\$25,000.00	\$27,500.00

received 22/6/15
s47F

Our preferred method of payment is by Direct Deposit (EFT): PLEASE QUOTE INVOICE NUMBER 128263 AS YOUR REFERENCE.
Remittance advices may be emailed to s47f@unisa.edu.au OR faxed to s47f

Electronic Funds Transfer Bank Account Details:

s47

DEPT OF HEALTH & AGEING
DEBTOR ID: DEPHEA00
INVOICE NO: 128263
AMOUNT: \$27,500.00

Credit Card Payment:

☐ VISA ☐ MasterCard

--	--	--	--

Expiry Date: ____ / ____ \$ ____

Cardholder Name: _____

Signature: _____

Cheques can be made payable to:
"University of South Australia".

s22

From: Workflow-System s47E(d) @Health.gov.au>
Sent: Wednesday, 29 April 2015 14:41
To: s22
Subject: Contract Registration record (4500116783) for University of South Australia for Analysis of bDMARDs and infections Con [SEC=UNCLASSIFIED]

The following Contract Registration record has been Confirmed by s22

Contract Registration Reference Number: 4500116783

Vendor: University of South Australia

Purpose: Analysis of bDMARDs and infections Proposal Type: Procurement Source of Funds: Health Departmental

Total Contract Value (incl GST): 27,500.00

Contract Description: Data analysis on biological anti-rheumatic drugs and infections Work Commencement Date: 07.04.2015

Contract Completion Date: 25.05.2015

Actioned by: s22

Action: Confirmed

Date: 29.04.2015

Time: 14:41:26

Comments:

confirmed

This is an automated message. Please do NOT respond to this email.

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH AND AGED CARE

s22

From: Workflow-System s47E(d) @Health.gov.au>
Sent: Thursday, 2 April 2015 15:20
To: s22
Subject: COMMITMENT APPROVAL record for University of South Australia for Analysis of bDMARDs and infectionsApproved. [SEC=UNCLASSIFIED]

The following COMMITMENT APPROVAL record has been Approved by Adriana Platona PLATONA.

COMMITMENT Number: 6000066884
Vendor: University of South Australia
Purpose: Analysis of bDMARDs and infections Proposal Type: Procurement Source of Funds: Health Departmental
Total Expenditure Requested (incl GST): 27,500.00
Expenditure extends to Financial Year: 2014-15

Actioned by: Adriana Platona PLATONA
Action: Approved
Date: 02.04.2015
Time: 15:20:21

Comments:
approved

This is an automated message. Please do NOT respond to this email.

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH AND AGED CARE

Under \$80,000 (GST Inclusive) Risk Profile Guide

Department of Health
Pharmaceutical Evaluation
Branch
s22

This Risk Profile Guide should be used as a framework to determine the risk profile of a procurement at the early stages of the procurement process and is used to reassess and manage the risk(s) throughout the process. This document is a guide only. Where specific agency methods exist, these should apply.

Why assess procurement risk?

Procurement effort should be proportionate to the risk profile of a procurement. As procurement risk increases, the procurement process and documentation demands greater rigor and level of detail. Certain risk factors, such as impact of and complexity in the procurement will influence the way the procurement process will be conducted.

The risk factor ratings below will help you to determine a procurement process that is proportionate to the procurement risk.

Risk Factor Ratings

The following risk factors should be considered to help you determine the risk profile of your procurement:			
Risk Factor	Risk		
	L	M	H
Impact			
<i>Potential for negative impact on the reputation of the organisation or government</i>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
<i>Potential for negative impact on the capability of the organisation</i>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<i>Potential for poor supplier performance</i>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<i>Potentially difficult to find replacement good/ service</i>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
Complexity			
<i>Potential for delivery of good/ service that does not meet requirements</i>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
<i>Potential for procurement process errors (e.g. if you are not using an existing arrangement such as a panel or a multi-use list)</i>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Overall costs			
<i>Potential for increase in procurement costs</i>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	Risk		
Overall Risk Profile	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Select **Low**, **Medium** or **High** risk ratings against each risk factor. Consider likelihood and consequence in your decision.

Left click mouse to select the appropriate option.


The overall risk profile is the rating with the most checks. In case of a tie, select the highest rating.

Under \$80,000 (GST Inclusive) Procurement Plan

Department of Health
Pharmaceutical Evaluation Branch
§22

This Procurement Plan document should be used to plan a procurement. It is important that you determine the risk profile of your procurement before using this document because you may not need to complete all sections depending on the level of risk.

What are you going to buy and why?

 You will need to attach:

- **Risk Profile**
(for **Low**, **Medium** risk)

A preliminary research project assessing the relationship between the use of biological disease modifying anti-rheumatic drugs (bDMARDs) and infections will be procured. This project forms part of preliminary research that may lead to a more formal review of the comparative safety, effectiveness or cost-effectiveness of bDMARDs.

(Complete for **Low**, **Medium** risk)
Describe what is being procured and why. Provide appropriate background information necessary for the delegate to review the course of action you are recommending.

Who will you consult?

The Post-Market Review section of Pharmaceutical Evaluation Branch has been consulted, as they have previously conducted similar procurement. The Department of Veteran's Affairs (DVA) will be consulted.

(Complete for low to **Medium** risk)
Provide details of consultations with any parties

What is the estimated value?

The estimated value of this procurement is approximately \$30,000. As the procurement value is less than \$80,000, the Additional Rules for Procurement above the Threshold in Division 2 of the Commonwealth Procurement Rule (CPR) do not apply.

(Complete for **Low**, **Medium** risk)
An estimated amount is acceptable. Estimated value should comprise all procurement costs (e.g. administrative) as well as the cost of the good/ service being procured (GST inclusive)

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH AND AGED CARE

How will suppliers be identified and selected?

The Department is interested in both milder infections requiring treatment with anti-infective medicines as well as serious infections requiring hospitalisation. This requires having access to a longitudinal data set that includes data on patients' use of bDMARDs, use of anti-infectives and hospitalisation data. Information on hospitalisations is not included in the PBS data internally available to our Division. A dataset containing a large number of patients is required due to relative rarity of severe refractory immune-mediated conditions. The DVA had a treatment population of 212,447 in December 2014 (Treatment population statistics - December 2014, Department of Veterans' Affairs).

The DVA has a contract with s47F

University of South Australia, under the Veteran's MATES program to undertake utilisation analyses of medicines. The utilisation analyses of anticoagulants, anti-dementia medicines, blood glucose test strips and Chronic Obstructive Pulmonary Disease (COPD) medicines arranged by the Post-Market Review section have all been undertaken under the Veterans' MATES contract. Utilisation analysis of medicines is a highly specialised field with a limited number of potential suppliers in Australia. s47F has provided the Department with high quality utilisation analyses at a cost that is generally below the quotes provided for comparable analyses by other organisations. In line with an efficient procurement process that provides value for money, the Department will contact s47F to quote for this work and will write to DVA to arrange for a work order to be issued under the MATES contract.

(Complete for **Low**, **Medium risk**)

Describe the method for selecting supplier (i.e. they may have previously satisfactorily provided similar supplies to your agency or are a representative sample of businesses advertised in the phone book). Include the number of suppliers approached and how they will be approached.

How will offers be evaluated?

Offers will be evaluated according to the selection criteria included in the Commonwealth's General Conditions of Offer.

The Health Evaluation Team will consist of:

s22 **Director, Drug Utilisation Section**

Procurement Method:

- ☐ Open
☒ Direct
☐ Pre Qualified

(Complete for **low to Medium risk**)

The team number should be commensurate with the risk level. For example, for a low risk procurement, it may be appropriate for a single person to act as the only team member.

Left click mouse to select the appropriate option.

Next Steps

Once you have completed the procurement plan, complete the risk profile template and attach both documents to your online SAP ESS Approval in Principle request to your COMMITMENT APPROVER.

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH AND AGED CARE

Under \$80,000 (GST Inclusive) Value for Money Evaluation

Department of Health
Pharmaceutical Evaluation
Branch
s22

This document describes the evaluation process used to determine value for money for a procurement. The findings and recommendations of an evaluation process are recorded below.

Background

NOTE
You will need to complete this document for low to **medium** risk procurements.

On 23 March 2015, we approached 1 Supplier by phone for a preliminary research project examining the relationship between the use of biological disease modifying anti-rheumatic drugs (bDMARDs) and the occurrence of infections. 1 offer/ quote was received.

The process followed for this procurement has complied with the *Commonwealth Procurement Rule* requirements for Division One procurements. A limited tender approach was considered commensurate with the scale and scope of this procurement.

(Complete for low to **Medium** risk)
Contact method can be phone, email or AusTender.

Evaluation Methodology

The offers were evaluated as set out in the *Commonwealth General Conditions of Offer* to determine the best value for money outcome for the Department of Health.

The evaluation team consisted of s22

(Complete for low to **Medium** risk)
Insert names of members of the evaluation team and any support staff including the specific roles and/or responsibilities for each.

Evaluation Rating

Very Good	The Offer satisfies the Selection Criterion to a very high standard and presents minimal or no risk to the Commonwealth and its claims are fully supported by the information provided.
Good	The Offer satisfies the Selection Criterion to a high standard and/or presents limited risk to the Commonwealth. The Respondent's claims, in the view of the Evaluation Committee (EC), are supported by the information provided.
Satisfactory	The Offer satisfies the Selection Criterion to a satisfactory degree and/or presents an acceptable level of risk to the Commonwealth. In the view of the EC, there are some minor deficiencies and shortcomings in the information provided.
Poor	The Offer barely satisfies the Selection Criterion and/or presents some degree of unacceptable risk to the Commonwealth. In the view of the EC, there are major deficiencies in the information provided.
Unsatisfactory	The Offer does not satisfy the Selection Criterion and/or presents an unacceptable level of risk to the Commonwealth.

A 'Poor' or 'Unsatisfactory' rating for one or more Selection Criteria will exclude the Respondent from being recommended.

The Selection Criteria are not weighted.

The quotes/ offers were evaluated as set out in the *Commonwealth General Conditions of Offer* to determine the best value for money.

Evaluation Methodology

Criteria	Respondent University of South Australia		
the extent to which the respondent's offer met the Commonwealth's requirement set out in the RFQ	Very good The respondent answered the requirements clearly		
the respondent's proven capacity to provide the requirement	Very good The respondent has proven capacity in providing similar projects of high standard to the Department on a number of occasions (through the panel arrangement)		
the total costs to be incurred by the Commonwealth	Very good The offer is considered to be a reasonable cost for the type of work		
Overall ie Value for Money (VFM)	Very good		

(Complete for low to **Medium** risk)

Findings of the Evaluation

1 offer received was compliant and fully assessed.

0 were non-compliant and, in accordance with the *Commonwealth General Conditions of Offer* were not further considered.

The evaluation team found that the offer from the University of South Australia provides the best value for money outcome for the Department of Health.

(Complete if using an evaluation panel)

Supplier Selection

In the Evaluation Team's opinion, the University of South Australia provided an offer that meets the needs of the project in terms of quality and price.

Use one of the four listed options or insert alternative text that is more specific to your process. Delete the other options.

Recommendation

The evaluation team unanimously recommends that the university of South Australia be contracted for \$27,500 GST inclusive to provide a utilisation report on the relationship between bDMARDs and infections. This decision is based on the evaluation team’s assessment that the offer from the University of South Australia provides the best value for money outcome for the Department of Health.

(Complete for low to *Medium* risk)

s22		

(Complete for low to *Medium* risk)
Number of Panel Members is commensurate with level of risk

Evaluation Team Chair

Date: 12/03/2024

Next Steps
For *low*, *medium* risk procurements, complete a COMMITMENT APPROVAL.

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH AND AGED CARE

SUPPLEMENT TO THE SPENDING PROPOSAL (PROCUREMENT)

1. PROCUREMENT DESCRIPTION

The Department is procuring an analysis of the utilisation of Pharmaceutical Benefits Scheme (PBS) listed biological disease modifying anti-rheumatic drugs (bDMARDs), to be undertaken by the University of South Australia, under the Department of Veterans' Affairs MATES contract. The analysis will focus on the relationship between the use of bDMARDs and occurrence of infections requiring treatment with anti-infective medicines or needing hospitalisation.

Further information on the analysis to be undertaken is contained in the attached scope of work agreed with the University of South Australia.

2. BACKGROUND/CONTEXT

At its February 2015 meeting, the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee requested an analysis examining the impact of bDMARD use on the occurrence of infections and impacts on antimicrobial prescribing. The use of bDMARDs has increased rapidly since the listing of etanercept in 2003. bDMARDs work by inhibiting pro-inflammatory cytokines that play an important role in the pathogenesis of inflammatory diseases and the immune system. They are known to increase the risk of infection.

Adriana Platona, Assistant Secretary, Pharmaceutical Evaluation Branch, verbally approved that a quotation for this work be sought from ^{s47F} [REDACTED], Quality Use of Medicines and Pharmacy Research Centre, University of South Australia. A quotation was sought from ^{s47F} [REDACTED] on 23 March 2015 and the quotation was received on 27 March 2015.

3. RATIONALE FOR USING A LIMITED TENDER APPROACH (DIRECTLY APPROACHING THE SUPPLIER)

DVA has a contract with ^{s47F} [REDACTED], Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, under the Veterans' MATES program to undertake utilisation analyses of medicines. The University of South Australia has undertaken utilisation analyses to support post market reviews, including anticoagulants, anti-dementia medicines and blood glucose test strips, for the Department under the Veterans' MATES contract.

Utilisation analysis of medicines is a highly specialised field with a limited number of potential suppliers in Australia. ^{s47F} [REDACTED] has provided the Department with high quality utilisation analyses at competitive cost. Under the DVA Veterans' MATES contract, ^{s47F} [REDACTED] is able to analyse the relationship between the utilisation of bDMARDs and the use of anti-infective medicines as well as hospitalisations for infectious diseases. DVA data is unique in that it has a large dataset on health care utilisation of both medicines and hospitalisation records for over 200,000 DVA beneficiaries. The PBS data available to the Department do not include patient level data on hospital admissions, and are thus not fit-for-purpose for this research.

Under the DVA Veterans' MATES contract, additional utilisation analyses can be requested by a work order. Previous projects have proven that leveraging the cooperative agency arrangement and directly approaching ^{s47F} [REDACTED] to quote for this work under the MATES contract is an efficient procurement process that is commensurate with the scale and

scope of the procurement and has a high likelihood of providing value for money to the Department.

4. ASSESSMENT OF VALUE FOR MONEY

The procurement will achieve value for money on the basis that the quoted price is comparable to the cost of similar utilisation analyses and that the University of South Australia has a good track record of providing high quality reports to the Department.

5. TOTAL COST OF PROCUREMENT

\$27,500 (GST inclusive)

6. COST CENTRE

s47E(d) (Departmental)

7. FORWARD COMMITMENT

Has FORWARD COMMITMENT been relied on in forming this proposal?

☐ YES ☒ NO

8. RISK MANAGEMENT

The Risk Management Plan:

- ☐ Is attached; or
- ☒ As this project is not considered to be high risk nor exceeds \$100,000, a formal risk assessment/management plan is not required. The risks are considered to be **low**/medium and the management measures include:
- The use of an established contract with a supplier.
 - Previous high quality performance of the supplier.

9. ANY ADDITIONAL CONDITIONS

The findings of this analysis may be used to initiate a Post-Market Review of bDMARDs. Post-market reviews of medicines are a sensitive topic for industry. Under the MATES contract, intellectual property is owned by DVA. Should the University wish to publish contract material, permission would need to be sought from DVA, who would subsequently consult the Department of Health.

Date cleared by PAS:

2/4/2015.

Project:

Analysis of BDMARD's end infections

Program Contact:

s22

The attached documentation has been cleared by the PAS and meets the legislative and procedural requirements outlined below:

No.	APPROVAL OF PROCUREMENT CONTRACT	Yes	No
	Commitment Approval		
	BACKGROUND		
1	Purpose identified	X	
2	Initial approval of project and in-principle expenditure (GST incl.) confirmed	X	
3	Has the project commenced prior to the date the delegate is approving the Commitment, and if so, has a justification been included? - NB Delegate must be advised that a breach of s23(3) and s23(1) may be reported if appropriate		X
4	Outcome of engagement process documented appropriately (either in this brief, or referenced in an outcome of a tender evaluation process brief)	X	
5	If it is <u>limited tendering</u> has a justification been provided (and the <u>CPRs</u> cited if the value is over \$80,000 for a procurement contract)?	X	
6	Has an analysis of the basis under which value for money was determined been included?	X	
7	If it is a consultancy has a justification been provided?	X	
	CONTRACTUAL ARRANGEMENTS		
8	Contract checked and any changes to standard terms and conditions cleared by LSB and rationale included in brief	H/A	
9	Has the matter of any specific confidentiality provisions been addressed?	H/A	
10	Does the contract include an option to extend?		X

No.	APPROVAL OF PROCUREMENT CONTRACT Commitment Approval	Yes	No
11	Schedule clearly written; performance measures(milestones and deliverables) are clear and appropriate	X	
12	Information required in reports is clearly described	X	
13	Payment regime against deliverables on acceptance not just receipt	X	
14	Insurance Guideline requirements met and certificates of currency for all required insurances provided (including certificates of currency to be checked annually for multi year contracts)	X	
SPECIFIC REQUIREMENTS			
15	<p>If the procurement involves any of the following activities, has the appropriate wording been included in the briefing and contract?</p> <ul style="list-style-type: none"> • Campaigns (e.g. communication activities) - must be advised to <u>Communications Branch</u>, to ensure compliance with guidelines regarding purchasing of advertising and other associated marketing activities • Surveys - any proposed survey of 50 or more businesses must be notified to the Statistical Clearing House in the Australian Bureau of Statistics • Research involving humans - clearance by the Ethics Committee - if the project includes a component of research involving humans it may require clearance by the <u>Departmental Ethics Committee or an alternative</u> • Capital Works (Construction – not IT Capital) has the Delegate has been advised that: <ul style="list-style-type: none"> • the proposed contractor is or will be accredited under the Building and Construction Industry Improvement Act 2005. • the OFSC will be informed of the successful contractor (if within the required threshold). • the Contractor is aware of their obligations under the Code and Guidelines and the program area will register the contract on eCode • Development of a Website/web content – Online Communications Bch and TG consulted • The Indigenous Opportunities Policy - for projects involving expenditure over \$5 million (\$6 million for construction) in regions where there are <u>significant Indigenous populations</u> – included in their tender • Open Source Software Policy - for all ICT procurements delegate has been advised that open source software has been considered equally alongside proprietary software during the evaluation of tenders/quotes. • Gateway Review Process for \$10 million for information technology (IT) projects; and \$20 million for procurement and infrastructure projects – DoFD contacted for assistance 		

No.	APPROVAL OF PROCUREMENT CONTRACT Commitment Approval	Yes	No
	VALUE OF PROJECT		
16	Funds availability confirmed <ul style="list-style-type: none"> BRE/Cost Centre advised? If sourced from Administered funds, is it confirmed that the rationale of the project is consistent with the purpose under which the administered funds were appropriated? 	X	
17	If contract value exceeds amount approved in-principle, has delegate been advised of rationale on a value for money basis?	N/A	
18	Authority to approve expenditure (Commitment - refer to Financial Delegations)	SAP	
19	Forward Commitment agreement addressed (If required)	N/A	
20	If the contractor is a small business, has the delegate been advised that the DoFD 30 day payment policy applies?	N/A	
	GENERAL		
21	Revised risk assessment included, and process for ongoing management and monitoring of risks included in brief. <ul style="list-style-type: none"> Has reporting content and timing been considered to manage risks. Is it confirmed that Terms and Conditions will be managed at each point of deliverables being accepted 	X	
22	Conflict of Interest issues considered and addressed	X	
23	External reporting requirements confirmed (OVER \$100K - Murray, OVER \$10k - AusTender, CONSULTANCY OVER \$10k - Annual Report)	X	
24	Requirements of Corporate Business Rule 2 – Information Management and Record Keeping met	X	
25	All requirements of the process are in accordance with the <u>Commonwealth Procurement Rules</u> : <ul style="list-style-type: none"> Division 1 for procurement under \$80,000 GST inclusive; or Division 2 for procurement \$80,000 GST inclusive and over 	X	
26	PAS comments incorporated	X	

No.	APPROVAL OF PROCUREMENT CONTRACT Commitment Approval	Yes	No
27	Post-project evaluation advised: PACD only: <ul style="list-style-type: none"> If value over PAR threshold (\$50K Contracts) letter of offer advises PAR will be undertaken If a multi-year project, does brief advise PAR will be undertaken annually? 	N/A under \$50K	

Note to Delegate: Limited tender under \$50k.

Utilizing existing DVA master agreement with
Selected Supplier

PAS Adviser Name: _____

S47F

PAS REF: 1921

PAS Adviser Signature _____

THIS DOCUMENT HAS BEEN RELEASED UNDER
 THE FREEDOM OF INFORMATION ACT 1982
 BY THE DEPARTMENT OF HEALTH AND AGED CARE

UNCLASSIFIED
For Official Use Only (FOUO)



Australian Government
Department of Health

Minute Adriana Platona
 Assistant Secretary
 Pharmaceutical Evaluation Branch

REQUEST TO ENGAGE CONTRACTOR TO UNDERTAKE AN ANALYSIS OF bDMARDs AND INFECTIONS

Purpose

To procure a preliminary research project assessing the relationship between the use of biological disease modifying anti-rheumatic drugs (bDMARDs) and infections.

This project was requested by the Drug Utilisation Sub-Committee and forms part of preliminary research that may lead to a more formal review of the comparative safety, effectiveness or cost-effectiveness of bDMARDs.

Background

The Department of Veterans' Affairs has previously allowed the Department to use DVA data through their Veterans' MATES program contract with the University of South Australia (UniSA). In the past, DVA has agreed to prepare a work order under the DVA/UniSA contract that is consistent with the schedule of work required for the procurement. Under the work order, the DVA requests that UniSA invoice the Department of Health for the payment of the agreed schedule of work.

Current situation

You provided verbal approval to s22 [REDACTED] Director, Drug Utilisation Section to approach a supplier and seek a quote for this project.

s47F [REDACTED] of UniSA has quoted \$27,500 (GST inclusive) for this work.

The following documents provide supportive information for this procurement:

- Procurement plan (Attachment 1)
- Risk profile guide (Attachment 2)
- Supplement to the spending proposal (Attachment 3)
- Quotation (Attachment 4)
- Value for Money Evaluation (Attachment 5)

A letter to DVA requesting a work order for this project is attached for your signature (Attachment 6).

For Official Use Only (FOUO)
UNCLASSIFIED

RECOMMENDATIONS

- R1. That you NOTE the attached procurement plan, risk profile guide and supplement to the spending proposal.

NOTED

- R2. That your ACCEPT the quotation from UniSA and value for money evaluation.

ACCEPTED/NOT ACCEPTED

- R3. That you APPROVE the COMMITMENT APPROVAL in SAP for \$27,500 (GST inclusive) for the analysis of bDMARDs and infections project, as outlined in the supportive documentation and quotation.

APPROVED/NOT APPROVED

- R4. That you SIGN the letter to the Department of Veterans' Affairs to arrange a work order for this project

SIGNED/NOT SIGNED

s22

Director
Drug Utilisation Section
1 April 2015

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH AND AGED CARE

s22

From: s22
Sent: Monday, 26 September 2022 10:14 AM
To: s22
Subject: RE: MARCH 2022 PBAC outcomes - SGLT 2 [SEC=OFFICIAL]

Thanks very much s22

From: s22 @health.gov.au>
Sent: Monday, 26 September 2022 10:12 AM
To: s22 @health.gov.au>
Subject: RE: MARCH 2022 PBAC outcomes - SGLT 2 [SEC=OFFICIAL]

Hi s22

The Department is awaiting proposals from the relevant sponsors that are compliant with the PBAC advice. So unfortunately, there is no indicative implementation date I can advise at this point.

Cheers,
s22

From: s22 @health.gov.au>
Sent: Monday, 26 September 2022 10:07 AM
To: s22 @health.gov.au>
Subject: MARCH 2022 PBAC outcomes - SGLT 2

Hi s22 ,

A member of DUSC s47F has asked about the progress of the following March 2022 PBAC recommendation:

PBAC recommended the restrictions for empagliflozin and dapagliflozin could be expanded to allow earlier subsidised access to SGLT2 inhibitors in patients with T2DM as add-on therapy to metformin if they have established cardiovascular disease (CVD) or are at high risk of CVD, without the requirement to have a specific unmet glycaemic target. The PBAC also requested the Department progress pricing and risk sharing negotiations with the sponsors to achieve a financial cap on the additional cost to the PBS over the forward estimates.

I understand s47F wants to note this as an update in the Veterans MATE's publication. I'd appreciate your advice on whether there is any information we can share with s47F at this time.

Thanks,
s22

From: s47F @unisa.edu.au>
Sent: Monday, 26 September 2022 9:59 AM
To: s22 @health.gov.au>
Subject: FW: MARCH 2022 PBAC outcomes - SGLT 2

REMINDER: Think before you click! This email originated from outside our organisation. Only click links or open attachments if you recognise the sender and know the content is safe.

Hi s22

I am not sure if you are able to tell me this, but we have an upcoming Veterans' MATES topic on diabetes. Are you able to advise on what date the restrictions will change for this recommendation for SGLT2 as add on to metformin for established CVD?

Thanks

s47F

the PBAC recommended the restrictions for empagliflozin and dapagliflozin could be expanded to allow earlier subsidised access to SGLT2 inhibitors in patients with T2DM as add-on therapy to metformin if they have established cardiovascular disease (CVD) or are at high risk of CVD, without the requirement to have a specific unmet glycaemic target. The PBAC also requested the Department progress pricing and risk sharing negotiations with the sponsors to achieve a financial cap on the additional cost to the PBS over the forward estimates.

Quality Use of Medicines and Pharmacy Research Centre
CEA-17
Clinical and Health Sciences
GPO 2471
Adelaide 5001
South Australia

s47F

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH AND AGED CARE

Work Order

WORK ORDER DETAIL	Contract Reference	DETAILS
Title		Department of Health initiative
Work Order Number		037
Purchase Order Number		N/A
Date of Order		7 April 2015
Customer	C (a)	Department of Veterans' Affairs on behalf of the Department of Health
Supplier	B (a)	University of South Australia
Specification of the Services to be provided	D (b)	<p>DVA Veterans' MATES data will be used to undertake the following analyses:</p> <p>Outcome: determine the rate of infections during use of bDMARDs.</p> <p>Infections will be measured by:</p> <p>a) hospital admissions for infections, and</p> <p>b) dispensings for anti-infectives.</p> <p>Outcome measures:</p> <ul style="list-style-type: none"> • Rate of hospital admissions (primary diagnosis ICD 10 codes A00-B99) for infection per 100 patient months of treatment • Rate of treatment with antibiotics (J01) (Number of antibiotic prescriptions dispensed per 100 patient months of treatment) • Rate of treatment with antivirals (J05) (Number of antiviral prescriptions dispensed per 100 patient months of treatment) • Rate of treatment with antifungals (J02) (Number of antifungal prescriptions dispensed per 100 patient months of treatment) <p>Outcomes will be adjusted for age and gender.</p>
Acceptance	G (b)	Department of Veterans' Affairs has requested a service from UniSA under the scope of the current Veterans' MATES agreement.
Details of Products and Services and method of purchase		The University of South Australia will provide data analysis on the relationship between utilisation of bDMARDs and occurrence of infections, as outlined in the above specification. This analysis will be presented as a written report and include: methods of analysis, results, interpretation of results and their representativeness to the total PBS population.
Specified Personnel	B(c)	s47F
Delivery Conditions	D (b)	The analysis is to be provided to the Department of Health, subject to final clearance Department of Veterans' Affairs.

Additional Information		Department of Health contact point is: Director, Drug Utilisation Section
Intellectual Property Rights	H (b)	Ownership of Intellectual Property remains vested with DVA.
Customer Furnished Items	F	N/A
Price and Timeframes		\$27,500 (GST Inclusive) Due date: 25 May 2015
Payment plan		The Department of Health will be invoiced for the services provided under this work order. Payment 28 days from receipt of invoice.
DVA Contact		s22
Signed for and authorised by Department of Veterans' Affairs Representative.		s47F
Signed for and on behalf of Contractor by Contractor's Contract Representative indicating that Contractor agrees to comply with the terms of the Contract created by this Work Order and the Terms of Contract		s47F Director, Pharmacy Programs Veterans' MATES Quality Use of Medicines and Pharmacy Research Centre University of South Australia

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH AND AGED CARE

s22

From: s22
Sent: Monday, 27 April 2015 4:04 PM
To: s47E(d)
Subject: FW: bDMARDs data request [DLM=For-Official-Use-Only]
Attachments: Veterans MATES Work Order - Dept Health initiative_Signed.pdf

s22

Assistant Director
 Drug Utilisation | Pharmaceutical Evaluation
 Department of Health
 Ph: (02) 6289 s22
 GPO Box 9848, Canberra ACT 2601
 Sirius building, Woden | s22

From: s22 @dva.gov.au]
Sent: Monday, 27 April 2015 3:56 PM
To: s22 @health.gov.au'
Cc: s22 @dva.gov.au; s47F ; s47F @unisa.edu.au
Subject: bDMARDs data request [DLM=For-Official-Use-Only]

Hi s22

Please find attached a signed work order for DoH's request for bDMARDs data from UniSA.

Thank you

s22

Pharmacy Programs | Primary Health Care
 Health and Community Services Division
 Department of Veterans' Affairs

s22

IMPORTANT

1. Before opening any attachments, please check for viruses.
2. This e-mail (including any attachments) may contain confidential information for the intended recipient. If you are not the intended recipient, please contact the sender and delete all copies of this email.
3. Any views expressed in this e-mail are those of the sender and are not a statement of Australian Government Policy unless otherwise stated.
4. Electronic addresses published in this email are not conspicuous publications and DVA does not consent to the receipt of commercial electronic messages.
5. To unsubscribe from emails from the Department of Veterans' Affairs (DVA) please go to http://www.dva.gov.au/contact_us/Pages/feedback.aspx, and advise which mailing list you would like to unsubscribe from.
6. Finally, please do not remove this notice.

s22

From: s22
Sent: Wednesday, 6 March 2013 12:53 PM
To: s47F @unimelb.edu.au; s47F @unisa.edu.au; s47F
Cc: s47E(d)
Subject: Conflict of Interest for DUSC teleconference [SEC=UNCLASSIFIED]

Importance: High

Hi s47F

Just a reminder to please address any potential conflict of interest in the meeting today.

By email last week I asked members to note any potential conflict of interest for the NOACs. No conflicts were raised.

We usually also ask for any additional or new potential conflicts identified to be raised verbally on the day of the meeting.

I have had a conversation with s47F today to clarify her role in the AF review. She does not believe that she has a conflict, and s47F agrees that there is no conflict. I have included a summary of s47F role (from the Department's perspective) in the email below.

s47F has confirmed with me that she has had no role in constructing any of the information in the 3 NOAC submissions to PBAC.

If you also agree that there is no conflict, we will record this in the minutes of the meeting.

If you wish to discuss with s47F beforehand her number is s47F.

Many thanks.

s22
 s22 | DUSC Secretary | Pharmaceutical Evaluation Section | Dept. of Health & Ageing | ☎ phone 02 6289 s22 | 📠 fax 02 6289 s22 | ✉ email s22 @health.gov.au

----- Forwarded by s22 /PBD/Health on 06/03/2013 12:36 -----

From: s22
To: s22 @Health.gov.au,
Cc: s22 @Health.gov.au
Date: 06/03/2013 12:16
Subject: Role of University of South Australia in the Review of Anticoagulation Therapies in Atrial Fibrillation [SEC=UNCLASSIFIED]

Role of University of South Australia in the Review of Anticoagulation Therapies in Atrial Fibrillation

The University of South Australia provided unpublished MATES data (from previous analyses) regarding rates of co-morbid conditions and use of particular concomitant medications among veterans with atrial fibrillation. This data was used in the Review report to show that:

- approximately 40% of the aged population have a minimum of three comorbidities;
- concomitant medicines used by veterans with atrial fibrillation - almost 30% of AF patients on aspirin, clopidogrel or warfarin monotherapy were co-prescribed NSAIDs or COX-2 inhibitors (12%, 10% and 7%, respectively) and
- about 45% of AF patients receiving warfarin were also receiving a PPI.

This data contributed to the overall picture that:

- these comorbid conditions, risk factors, and medicines may lead to drug interactions and disease state interactions with medicines used for stroke prevention, which poses a challenge for the management of stroke prevention in AF.
- The rates of concomitant medication use in the pivotal clinical trials of the new oral anticoagulants may not accurately represent the rates of concomitant medication in the Australian population likely to take these medicines in clinical use.

More complex data requests were discussed with the University of South Australia, (for example, around ways to use MATES data to estimate the number of INR tests per year per AF patient on warfarin), however it was agreed that such data would be too confounded to be useful and these requests were not progressed.

s22 ~ Pharmaceutical Policy Branch
Pharmaceutical Benefits Division ~ Dept of Health & Ageing
Phone: 6289 s22 ~ E-mail: s22 @health.gov.au

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH AND AGED CARE



TAX INVOICE

DEPT OF HEALTH & AGEING
ATTN: s22
GPO BOX 9848
CANBERRA ACT 2601

Invoice No:	128263
Date:	22/06/2015
Debtor Code:	DEPHEA00
Your Ref.	
Your ABN:	83 605 426 759

Please direct initial enquiries to s47F

Description			Exclusive GST	GST	Inclsv Amt
Work Order (WO:37) 7/4/2015					
Work Undertaken for Dept of Health					
As Per W/O Dept of Veterans Affairs					
Determine rate of Infections-bDMARDs			25,000.00	2,500.00	27,500.00
Terms: Net	14	days	Total Amount Due:	\$25,000.00	\$27,500.00

Our preferred method of payment is by Direct Deposit (EFT): PLEASE QUOTE INVOICE NUMBER 128263 AS YOUR REFERENCE.
Remittance advices may be emailed tcs47F@unisa.edu.au OR faxed to [+61 8 8302 4444](tel:+61883024444)

Electronic Funds Transfer Bank Account Details:

s47

DEPT OF HEALTH & AGEING
DEBTOR ID: DEPHEA00
INVOICE NO: 128263
AMOUNT: \$27,500.00

Credit Card Payment:

☐ VISA ☐ MasterCard

--	--	--	--

Expiry Date: ____ / ____ \$ _____

Cardholder Name:

Signature: _____

Cheques can be made payable to:
"University of South Australia".



Australian Government
Department of Veterans' Affairs

Ms Adriana Platona
Assistant Secretary
Pharmaceutical Evaluation Branch
Department of Health

s22

GPO Box 9848
CANBERRA ACT 2601

Dear Ms Platona

Department of Health request for data relating to bDMARDs

s37(2)(a)



The contract under which these requests have been made possible will expire on 30 June 2015. While this request will be completed before this date, any future requests for data will need to be assessed under new arrangements.

If you have any questions or concerns in regard to this issue, please contact s22
Director, Pharmacy Programs Section by phone on s22 or by email at
s22 @dva.gov.au.

Yours sincerely,

s47F

Letitia Hope
Assistant Secretary
Primary Health Care Branch

23 April 2015



Australian Government
Department of Health and Ageing

Letitia Hope
Assistant Secretary
Primary Health Care Branch
Department of Veterans' Affairs
GPO Box 9998
CANBERRA ACT 2601

Dear Ms Hope

Veterans' MATES Contract with the University of South Australia

The Department of Health is undertaking preliminary research on the utilisation of biological disease modifying anti-rheumatic drugs (bDMARDs) listed on the Pharmaceutical Benefits Scheme (PBS), with a focus on the relationship between bDMARD use and infections. I am writing to seek your agreement for a work order to be created under the provision of DVA's current Veterans' MATES contract with the University of South Australia, to undertake an analysis of the utilisation of bDMARDs using PBS data. I have attached the requirements and scope of the work to be undertaken.

s37(2)(a)

This letter and attachment could form the basis for an agreement between our Departments, subject to your written acceptance. Your reply by 13 April 2015 would be greatly appreciated. With your agreement, I would like the University to invoice the Department of Health directly.

If you require further clarification, please contact s22 Director, Drug Utilisation Section on (02) 6289 s22. I would like to thank you and your team for your ongoing assistance in support of PBS utilisation analysis.

Yours sincerely

s47F

AV Adriana Platona
Assistant Secretary
Pharmaceutical Evaluation Branch

7 April 2015

SCOPE OF WORK - Preliminary research on the utilisation of biological disease modifying anti-rheumatic drugs (bDMARDs) listed on the Pharmaceutical Benefits Scheme (PBS), with a focus on the relationship between bDMARD use and infections

Background

The Department of Health requires a preliminary research project examining the impact of use of biological disease modifying anti-rheumatic drugs (bDMARDs) on the occurrence of infections and impacts of antimicrobial prescribing. This project forms part of preliminary research that may lead to a more formal review of the comparative safety, effectiveness or cost-effectiveness of bDMARDs.

The PBS data available to the Department of Health does not include patient level data on hospital admissions, and are thus not fit-for-purpose for this project. The Department of Health understands that, under the DVA Veterans' MATES contract, ^{s47F} is able to analyse the relationship between the utilisation of bDMARDs and the use of anti-infective medicines as well as hospitalisations for infectious diseases.

Specification of requirements

Specification of the services to be provided	<p>DVA Veterans' MATES data will be used to undertake the following analyses:</p> <p>Outcome: determine the rate of infections during use of bDMARDs.</p> <p>Infections will be measured by:</p> <ol style="list-style-type: none"> hospital admissions for infections, and dispensings for anti-infectives. <p>Outcome measures:</p> <ul style="list-style-type: none"> Rate of hospital admissions (primary diagnosis ICD 10 codes A00-B99) for infection per 100 patient months of treatment Rate of treatment with antibiotics (J01) (Number of antibiotic prescriptions dispensed per 100 patient months of treatment) Rate of treatment with antivirals (J05) (Number of antiviral prescriptions dispensed per 100 patient months of treatment) Rate of treatment with antifungals (J02) (Number of antifungal prescriptions dispensed per 100 patient months of treatment) <p>Outcomes will be adjusted for age and gender.</p>
--	--

Details of product	The University of South Australia will provide data analysis on the relationship between utilisation of bDMARDs and occurrence of infections, as outlined in the above specification. This analysis will be presented as a written report and include: methods of analysis, results, interpretation of results and their representativeness to the total PBS population.
Delivery conditions	The analysis is to be provided to the Department of Health, subject to final clearance by the Department of Veterans' Affairs.
Price and timeframes	Cost: \$25,000 (GST exclusive) Total cost: \$27,500 (GST inclusive) 1. Acceptance of final report – due 25 May 2015 \$27,500 (GST inclusive)
Payment plan	The Department of Health will be invoiced for the services provided under this work order. Payment 28 days from receipt of invoice.

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES



Australian Government

Department of Health and Ageing

RECEIVED

02 FEB 2012

No: 006
General Manager
Services Division

s22

A/g General Manager
Services Division
Department of Veterans Affairs

Dear s22

Access to Veterans Affairs data

The Government, as part of the 2011-12 Budget measure, *Improving sustainability of the PBS through enhanced post-market surveillance*, has invested in a coordinated and structured approach to monitoring Pharmaceutical Benefits Scheme (PBS) listed medicines in use, through the introduction of ongoing reviews of medicines use in clinical practice. These reviews are intended to provide stronger evidence and support to inform the Pharmaceutical Benefits Advisory Committee (PBAC) consideration and decision making, and ensure medicines use remains appropriate and consistent with the original recommendation to list.

The Government recently announced the first of these reviews - a review of Anticoagulation Therapies in Atrial Fibrillation, which is being conducted by s47F

The Review will inform the Government on options for improving the health outcomes of patients treated with anticoagulant therapies, including optimising the use of currently available treatments in Australia as well as the future role of newer therapies for the treatment of atrial fibrillation, such as dabigatran (Pradaxa®). The Terms of Reference for the Review, which are now publicly available on pbs.gov.au, are to:

- report on current and future options for improving the health outcomes of patients with atrial fibrillation treated with oral anticoagulants;
- report on modes of health system delivery which may be used to optimise the use of currently available anticoagulants;
- report to what extent optimisation of the use of currently available anticoagulant treatments used in patients with atrial fibrillation would improve health outcomes and at what cost;
- examine the future role of newer anticoagulant therapies for atrial fibrillation; and
- report on any other matter relevant to items a to d above and on any other matters referred to it by the Minister.

A key part of the review will require looking at previously conducted studies and any available data relating to the use of anticoagulants.

Representatives from my Division have already met with colleagues from DVA, including s47F s47F to discuss the review. It is clear that DVA already has an established history in utilising pharmaceutical data on the veteran population to monitor usage patterns and

inform quality improvement activity. The work DVA has already undertaken in collecting data on pharmacy prescribing and usage for the Veterans' MATES program could provide a useful indicator for other population groups also using medicines under this review.

s37(2)(a)



With your agreement, data provided for this review will be used to inform the ongoing discussions at the reference group and the report being prepared by s47F for consideration by the PBAC and the Minister for Health.

This review is the first of what will be a number of reviews to be conducted. I would therefore like to seek your cooperation in ensuring that officers from our departments continue to work closely in sharing relevant information for this and any subsequent reviews.

s22 Director, Operational Policy and Monitoring Section (6289 s22) is the day to day contact officer if you have any questions in relation to this request.

Thank you in advance for your assistance in this matter and I will ensure that DVA is kept informed at all stages of our reviews.

Yours sincerely

s47F



A/g Assistant Secretary
Pharmaceutical Policy Branch

31 January 2012



Australian Government
Department of Veterans' Affairs

ACT OFFICE

Ms Tracey Duffy
 A/g Assistant Secretary
 Pharmaceutical Policy Branch
 Department of Health and Ageing

s22

GPO Box 9848
 CANBERRA ACT 2601

Dear Ms Duffy

I am writing in response to your letter of 31 January 2012 concerning your department's 2011-12 Budget initiative *Improving sustainability of the PBS through enhanced post-market surveillance* and access to the Department of Veterans' Affairs (DVA) data in support of this initiative.

s37(2)(a)

DVA has commenced work with the UniSA to identify appropriate material for s47F review as discussed at the January 2012 meeting between DVA and your staff. This information will be provided progressively over the coming weeks, though the data analysis will not be to the depth envisaged under the parameters of original Budget proposal due to the review's time constraints.

s37(2)(a)

The DVA liaison for this initiative is s22 Director, Pharmacy & Health Technology Policy and he can be contacted on 02 6289 s22

Thank you for providing DVA the opportunity to support this activity and the recognition of the work by the UniSA in the Veterans' MATES program. I look forward to the progress of the review and the future opportunities it will provide both our departments.

Yours sincerely

s47F



24 February 2012

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH AND AGED CARE



Australian Government

Department of Health and Ageing


112

22

Judy Daniel
First Assistant Secretary
Health & Community Services Division
Department of Veterans' Affairs
GPO Box 9998
CANBERRA ACT 2601

s47F

for advice



Dear Ms Daniel

Veterans' MATES Contract with the University of South Australia

s37(2)(a)

DVA has already provided DoHA with statistical information for the current Review of Anticoagulant Therapies in Atrial Fibrillation, which has proven very useful in informing the Review and ^{s47F} Report. In recent weeks, we have received authorisation to pursue a number of new post-market reviews and DoHA believe the Veterans' MATES program could provide further meaningful analysis. As part of preliminary discussions with DVA about these additional reviews I understand that DVA may have particular interest in the reviews on chronic obstructive pulmonary disease, anti-dementia drugs, and diabetes.

s37(2)(a)

The Pharmaceutical Policy Branch considers that this letter and attachment could form the basis for agreement between our Departments, subject to your written acceptance of our proposal.

If you require further clarification, or have any questions, please do not hesitate to contact ^{s22} Director, Operational Policy and Monitoring Section via telephone (02) 6289 ^{s22}

I would like to thank you and your team for your assistance to date, as well as your ongoing cooperation with DoHA in support of these post-market reviews.

Yours sincerely

s47F




Pharmaceutical Policy Branch

6 June 2012

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH AND AGED CARE

Proposed Schedule for Veterans' MATES

University of South Australia will provide data analysis on four classes of drug usage as outlined in the following table. This analysis will be presented in four separate written reports and include: the methods of analysis; results; interpretation of the results and their representativeness to the PBS population.

Project	Scope/Questions	Timing	Cost
1) Anticoagulant Therapies in Atrial Fibrillation (AF) Review	<ul style="list-style-type: none"> Calculate the percent of people with AF on warfarin who are also: <ul style="list-style-type: none"> on the following medicines concomitantly: <ul style="list-style-type: none"> ARB or ACE inhibitor Beta-blocker Amiodarone verapamil have the following co-morbidities: <ul style="list-style-type: none"> prior stroke or TIA prior MI with diabetes with heart failure with hypertension Calculate the percent of AF patients on warfarin who had at least one INR test subsidised through MBS. <p><i>If available from data:</i></p> <ul style="list-style-type: none"> Calculate the percentage of AF patients on warfarin, whose warfarin was initiated in hospital compared to the percentage of patients whose warfarin was commenced in the community setting Calculate average INRs or average creatinine levels <p><i>The number of DVA patients accessing portable INR monitors and strips through the DVA's RAP (Rehabilitation Appliances Program)</i></p>	29 June 2012	\$47 

s47	31 July 2012	<ul style="list-style-type: none"> Identify the extent other therapeutic classes of medicines (particularly those with anti-cholinergic effects) are prescribed prior to initiating a CEI and those that are prescribed concomitantly with CEI's. Persistence analysis of patients on CEI's and memantine. Link initiation of PBS CEI's and memantine and continuation at 6 months to the MBS items for MMSE and other items for medical assessment of dementia. Where possible replicate parts of these analyses in a sample cohort of patient level PBS data made available to the University of SA by the Pharmaceutical Policy Branch. 	2) Anti-dementia Drugs Review
s47	12 weeks from commencement	<ul style="list-style-type: none"> The proportion of use of COPD specific medicines prescribed in COPD Vs Asthma vs Other or combined respiratory conditions. The extent of monotherapy and concomitant use of the PBS medicines restricted for use in COPD. 	3) Chronic Obstructive Pulmonary Disease (COPD) medicines Review
s47	16 weeks from commencement	<ul style="list-style-type: none"> Identify if there are indicators in both PBS and other health data of adverse clinical events that are associated with newer oral anti-diabetic agents. (this needs to be discussed/informed by TGA) Analyse utilisation of blood glucose test strips in type 2 diabetics and explore any possible relationship to outcomes such as hypoglycemic events, hospitalisations ect. 	4) Diabetes Review of oral hypoglycaemic agents.



Australian Government
Department of Veterans' Affairs

ACT OFFICE

Ms Tracey Duffy
A/g Assistant Secretary
Pharmaceutical Policy Branch
Department of Health and Ageing
s22

GPO Box 9848
CANBERRA ACT 2601

Dear Ms Duffy

Tracey

Thank you for your letter of 6 June 2012 concerning the Department of Health and Ageing's (Health and Ageing) 2011-12 Budget initiative, *Improving sustainability of the PBS through enhanced post-market surveillance*, and support of this initiative by the Department of Veterans' Affairs (DVA).

s37(2)(a)

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH AND AGEING CARE

I look forward to working with you to support this initiative and to promote the achievements of the Veterans' MATES program and the University of South Australia.

s47F

Health & Community Services Division

7 June 2012

s22

From: s22 @health.gov.au> on behalf of s47E(d) @health.gov.au>
Sent: Friday, 30 October 2020 2:06 PM
To: s47F
Cc: s47E(d); s47F @nps.org.au; contracts@nps.org.au; NPSMedicineWiseContracts@nps.org.au
Subject: FW: Notification of non-grant work: DVA Mates [SEC=OFFICIAL]

Dear s47F

I refer to NPS MedicineWise Notification Ref#: 2020/32 Veterans MATES -NPS MedicineWise contribution to the module development and planning activities.

The previous and current grants have funded the development of Therapeutic Programs. As highlighted in the Review of NPS MedicineWise's delivery of the grant, it is critically important that the grant does not cross-subsidise NPS MedicineWise's commercial activities. The Review also highlighted that the MATES Program also implemented similar projects at the same time.

The Department has noted this work as cross-subsidisation of NPS MedicineWise's commercial activities with grant. This work has used at minimum the formative research for the Opioid program funded under the QUM grant which is cross-subsidisation. NPS MedicineWise have also reported that they are engaging with MATES Program on other Therapeutic Programs NPS are responsible for, this includes meetings to develop material on the Heart Failure Program.

Therefore, based on these details the Department does not agree with the statements made in NPS MedicineWise notification regarding that net revenue be retained by NPS. While, the Department notes the contract with Department of Veterans Affairs (DVA) - University of South Australia commenced prior to the current funding agreement coming into effect there is cross subsidisation. Therefore, the Department approves the NPS MedicineWise proposal on the condition that all net revenue attributable to work undertaken be treated as grant funds under Schedule 5 b). NPS MedicineWise will be required to report specifically on this through the financial reporting.

Regards,

s22

Director (Acting), Quality Use of Medicines

Quality Use of Medicines

Technology Assessment and Access Division | Health Resourcing Group
 Pricing & PBS Policy Branch
 Australian Government Department of Health
 s47E(d) @health.gov.au
 GPO Box 9848, Canberra ACT 2601, Australia

The Department of Health acknowledges the Traditional Custodians of Australia and their continued connection to land, sea and community. We pay our respects to all Elders past and present.

From: s47F @nps.org.au>

Sent: Thursday, 15 October 2020 1:16 PM

To: s47E(d) [redacted] @health.gov.au>; s22 [redacted] @health.gov.au>; s22 [redacted] @health.gov.au>

Cc:

Subject: Notification of non-grant work: DVA Mates

REMINDER : Think before you click! This email originated from outside our organisation. Only click links or open attachments if you recognise the sender and know the content is safe.

Dear QUM Team,

Please find attached notification of non-grant work: PHN Immunisation

This is notification 4 of 5.

We look forward to receiving you feedback.

Kind regards

s47F [redacted]

s47F [redacted]

Business Operations Manager
Strategy, Programs and Delivery
Business Operations



**NPS
MEDICINEWISE**

Level 7 / 418a Elizabeth St
Surry Hills NSW 2010
PO Box 1147
Strawberry Hills
NSW 2012

P. (02) 8217 8609
F. (02) 9211 7578
s47F [redacted] @nps.org.au
www.nps.org.au

Independent, not-for-profit and evidence based,
NPS MedicineWise enables better decisions
about medicines, medical tests and other health
technologies.



Please consider the environment before printing this email

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH AND AGED CARE

Notification to the Department of Health concerning:

Veterans MATES – NPS MedicineWise contribution to module development and planning activities extension

NPS MedicineWise Submission Ref: 2021/32A

Funder: Department of Veterans Affairs (DVA) - University of South Australia

Summary of Proposed Project:

We refer to previous notification reference 2020/32 concerning the DVA Mates project (copy of notification and Department's response attached for ease of reference).

1. We requested the Department reconsider its determination on the 22 February and again on 14 May. We would be grateful for a response to our request.
2. The Department of Veteran Affairs (University of South Australia) has offered NPS MedicineWise an extension of the current contract for an additional 6-month period ending 31 December 2021. The contract is on the almost identical terms as the previously notified contract and all matters as per the original contract remain the same, but the following additional information is relevant to assist Health's considerations:
 - a) NPS MedicineWise would receive a total payment of \$14,346 (ex GST) for the 6-month period to 31 December 2021.
 - b) NPS MedicineWise projects Net Revenue of \$2,866 will be produced for the extended 6-month period. Subject to the Department's response, NPS MedicineWise proposes to commit this Net Revenue to its reserves.
 - c) NPS MedicineWise has been informed that topics for module development would be diuretics and then either post-traumatic stress disorder or chronic pain (from a psychological 'explain pain' perspective). Of these 3 possible topics during this period (1 to be confirmed by the funder), there is some degree of cross over with grant funded programs in only 1 (possible) topic, namely chronic pain.

As per information previously provided, the contributions NPS MedicineWise are contractually required to provide to this project are exclusively from skill and expertise of staff. NPS MedicineWise is not contractually required to contribute any Asset either funded by the Grant or otherwise.

Please confirm that NPS MedicineWise may proceed with the extension. We would be grateful for confirmation of the treatment of Net Revenue for the project (including the extension if it is approved).

Proposed Commencement Date and Project Period: 1 July 2021 – 31 December 2021

Have Grant Funds been used, or will Grant Funds be used, in connection with this project? No

Funding to NPS MedicineWise: NPS MedicineWise will receive \$14,346 plus GST. This will include Net Revenue of \$2,866.

Grant Assets or IP utilised as part of the Project

Grant funded intellectual property used as part of this project:

- Where appropriate, Veterans MATES modules include external links to content on NPS MedicineWise website.

Grant funded Assets used as part of this project:

- Office items would be utilised in the project namely basic office infrastructure including furniture and computers (as used by those staff for communications, updating content and the provision of support).

The cost attributable to the utilisation of these items will be accounted for in NPS MedicineWise overhead allocation and paid for by the project funding and not by Grant funding. Timesheets would be used to ensure staff effort on this project is not paid for by Grant funding.

NPS MedicineWise risk assessment

NPS MedicineWise has undertaken a risk assessment and considers this non-Grant project:

- poses low financial risk to Grant Program (with appropriate financial controls in place) and very low financial risk to NPS MedicineWise.
- is not a duplication, is not a similar project and is not an overlap of, Grant funded Activity.
- aligns closely the purpose of the Grant Program
- aligns with the mission of the Grant Agreement and that of NPS MedicineWise in supporting QUM.
- does not present a risk of compromise to NPS MedicineWise independence in the QUM ecosystem.
- presents low risk in terms of any conflicts (perceived, actual or potential) on NPS MedicineWise' unbiased ability to deliver the Grant activity.
- Is unlikely to damage the reputation of NPS MedicineWise or the Commonwealth.

NPS MedicineWise notification position

Staff effort for this project will be recorded in time sheets and paid for by the project income (and therefore not paid for by the Grant).

NPS MedicineWise will ensure that all project costs (including all staff effort), all direct costs and use of basic office items and other Assets are attributed to the project funding and not to Grant funding.

NPS MedicineWise proposes to take the Net Revenue to its reserves. This will support Grant Activity by helping to ensure NPS MedicineWise is a viable independent organisation not entirely dependent upon Grant funds.

28 June 2020

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH AND AGED CARE

s22

From: s22
Sent: Wednesday, 30 June 2021 4:06 PM
To: s47F
Cc: s47E(d); s22; s47F @nps.org.au; contracts; NPS MedicineWise Contracts
Subject: Notification 2021/32A of non-Grant work_DVA MATES extension [SEC=OFFICIAL]
Attachments: 2020_32_DoH Opportunity Submission DVA Mates.pdf; 2021_32a_DoH Opportunity Submission_DVA MATES extension.docx
Categories: s22

Dear s47F

I refer to NPS MedicineWise Notification Ref#: 2021/32A Veterans MATES -NPS MedicineWise contribution to the module development and planning activities.

The Department has agreed to NPS MedicineWise extending their contract end date with DVA from 30 June 2021 to 31 December 2021.

This approval is provided on the condition that NPS MedicineWise contribute 50% (\$1,433.00 approximately) of the net profit for the six month period (30 June to 31 December 2021) to Schedule 5a grant flexible funds. This decision is based on the likelihood of a cross-over with Grant material.

Please note that the Department's decision of 30 October 2020, that *'all net revenue attributable to work undertaken be treated as grant funds under Schedule 5b'* still stands for work undertaken for the period prior to 30 June 2021.

The Department's approval to proceed is only provided for the term of the Grant and does not extend beyond the Program Completion Date, being 30 June 2022.

The Department's approval is given on the basis of the information provided. If there is any material change to the scope of the work, or to the Net Revenue derived from it, please let me know as the Department's approval may need to be reconsidered or qualified.

Regards,

s22

Director – Quality Use of Medicines

Technology Assessment and Access Division
Pricing & PBS Policy Branch
Australian Government Department of Health
GPO Box 9848, Canberra ACT 2601, Australia

The Department of Health acknowledges the Traditional Custodians of Australia and their continued connection to land, sea and community. We pay our respects to all Elders past and present.

From: s47F
Sent: Wednesday, 30 June 2021 12:29 PM
To: s47E(d) ; s22
Cc: contracts ; NPS MedicineWise Contracts
Subject: Notification of non-Grant work_DVA MATES extension

REMINDER: Think before you click! This email originated from outside our organisation. Only click links or open attachments if you recognise the sender and know the content is safe.

Dear QUM Team,

Please find attached a notification of non-grant work relating to an extension of the DVA Mates program.

Kind regards

s47F

s47F

Business Operations Manager
Strategy, Programs and Delivery
Business Operations



Level 7 / 418a Elizabeth St
Surry Hills NSW 2010
PO Box 1147
Strawberry Hills
NSW 2012

P. (02) 8217 8609
F. (02) 9211 7578
s47F@nps.org.au
www.nps.org.au

Independent, not-for-profit and evidence based,
NPS MedicineWise enables better decisions
about medicines, medical tests and other health
technologies.



Please consider the environment before printing this email

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1982
BY THE DEPARTMENT OF HEALTH AND AGED CARE

Notification to the Department of Health concerning:

Veterans MATES – NPS MedicineWise contribution to module development and planning activities extension for 2022

NPS MedicineWise Submission Ref: 2022/32B

Funder: Department of Veterans Affairs (DVA) - University of South Australia

Summary of Proposed Project:

We refer to previous notification reference 2020/32 and 2021/32A concerning the DVA Mates project.

1. The Department of Veteran Affairs (University of South Australia) has offered NPS MedicineWise an extension of the current contract for an additional 12-month period ending 31 December 2022. This notification concerns activities between 1 January and 30 June 2022.
2. The contract is on the identical terms as the previously notified contract and all matters as per the original contract remain the same, but the following additional information is relevant to assist Health's considerations:
 - a) NPS MedicineWise would receive a total payment of **\$14,347** (ex GST) for the 6-month period to 30 June 2022.
 - b) NPS MedicineWise projects Net Revenue of \$1,300 will be produced for the 6-month period. Subject to the Department's response, NPS MedicineWise proposes to commit this Net Revenue to its reserves.
 - c) NPS MedicineWise has been informed that there will be two topics for module development during this period. These will be:
 - i) chronic pain (from a psychological 'explain pain' perspective),
 - ii) reducing the burden of common medicine related symptoms,

Of the 3 confirmed/possible topics during this period, there is a limited (i.e. some) degree of cross over with grant funded programs in 1 topic, namely chronic pain. The second topic ((ii) above) has a significantly wider scope than the recent NPS MedicineWise anticholinergic burden program.

Further justification for why there is limited crossover is that the focus of the pain program resources is primarily on supporting GPs to educate their veteran patients on better understanding their pain including the latest evidence for brain retraining and neuroplasticity, with a secondary focus on the place of opioids and ways to support patients reduce their opioid use.

The second topic has a much wider scope than medicines related symptoms associated with anticholinergic medicines but will include adverse effects of cardiovascular medicines and medicines for GORD, COPD/Asthma and diabetes, which are not included within the scope for the NPS MedicineWise anticholinergic medicines program. Hence limited crossover in both program.

- d) As per information previously provided, the contributions NPS MedicineWise are contractually required to provide to this project are exclusively from skill and expertise of staff. NPS MedicineWise is not contractually required to contribute any Asset either funded by the Grant or otherwise.

Please confirm that NPS MedicineWise may proceed with the extension. We would be grateful for confirmation of the treatment of Net Revenue for extension of this project if it is approved.

Proposed Commencement Date and Project Period: 1 January 2022 – 30 June 2022

Have Grant Funds been used, or will Grant Funds be used, in connection with this project? No

Funding to NPS MedicineWise: NPS MedicineWise will receive **\$14,347** plus GST. This will include projected Net Revenue of \$1,300.

Grant Assets or IP utilised as part of the Project

Grant funded intellectual property used as part of this project:

- Where appropriate, Veterans MATES modules include external links to content on NPS MedicineWise website.

Grant funded Assets used as part of this project:

- Office items would be utilised in the project namely basic office infrastructure including furniture and computers (as used by those staff for communications, updating content and the provision of support).

The cost attributable to the utilisation of these items will be accounted for in NPS MedicineWise overhead allocation and paid for by the project funding and not by Grant funding. Timesheets would be used to ensure staff effort on this project is not paid for by Grant funding.

NPS MedicineWise risk assessment

NPS MedicineWise has undertaken a risk assessment and considers this non-Grant project:

- poses low financial risk to Grant Program (with appropriate financial controls in place) and very low financial risk to NPS MedicineWise.
- Is synergistic with grant funded activity - there is an overlap in relation to one topic but the project is not a duplication of Grant funded Activity.
- aligns closely the purpose of the Grant Program

- d) aligns with the mission of the Grant Agreement and that of NPS MedicineWise in supporting QUM.
- e) does not present a risk of compromise to NPS MedicineWise independence in the QUM ecosystem.
- f) presents low risk in terms of any conflicts (perceived, actual or potential) on NPS MedicineWise' unbiased ability to deliver the Grant activity.
- g) Is unlikely to damage the reputation of NPS MedicineWise or the Commonwealth.

NPS MedicineWise notification position

Staff effort for this project will be recorded in time sheets and paid for by the project income (and therefore not paid for by the Grant).

NPS MedicineWise will ensure that all project costs (including all staff effort), all direct costs and use of basic office items and other Assets are attributed to the project funding and not to Grant funding.

NPS MedicineWise proposes to take the Net Revenue to its reserves.

7 February 2022

THIS DOCUMENT HAS BEEN RELEASED UNDER
THE FREEDOM OF INFORMATION ACT 1992
BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

s22

From: s47E(d)
Sent: Friday, 11 February 2022 11:44 AM
To: s47F
Cc: s47E(d); s47F @nps.org.au; contracts; NPS MedicineWise
Subject: Contracts
 Notification of non-grant work: DVA MATES extension - 2022

Dear s47F

I refer to NPS MedicineWise Notification Ref#: 2022/32B DVA Mates extension 2022 (Revised version).

The Department has retrospectively approved NPS MedicineWise extending their contract with the DVA Mates for the period 1 January to 30 June 2022 and for NPS MedicineWise to take up to \$1,300 in net profits to their reserves.

The Department is not able to approve any work post 30 June 2022 as it falls outside the current grant funding agreement.

The Department's approval to proceed is only provided for the term of the Grant and does not extend beyond the Program Completion Date, being 30 June 2022.

The Department's approval is given on the basis of the information provided. If there is any material change to the scope of the work, or to the Net Revenue derived from it, please let me know as the Department's approval may need to be reconsidered or qualified.

Regards

s22

Director, Quality Use of Medicines

Technology Assessment and Access Division
 Pricing & PBS Policy Branch
 Australian Government Department of Health
 Location: Sirius Building s22
 GPO Box 9848, Canberra ACT 2601, Australia

The Department of Health acknowledges the Traditional Custodians of Australia and their continued connection to land, sea and community. We pay our respects to all Elders past and present.

From: s47F @nps.org.au>
Sent: Monday, 7 February 2022 11:02 AM
To: s47E(d) @health.gov.au>
Cc: s47E(d) @health.gov.au>; s22 @health.gov.au>; s22 @health.gov.au>; s47F @nps.org.au; contracts <contracts@nps.org.au>; NPS MedicineWise Contracts <NPSMedicineWiseContracts@nps.org.au>
Subject: RE: [EXTERNAL] - [SEC=OFFICIAL] FW: Notification of non-grant work: DVA MATES extension - 2022

REMINDER: Think before you click! This email originated from outside our organisation. Only click links or open attachments if you recognise the sender and know the content is safe.

Hi s22

Please find attached the updated notification of non-grant work: DVA MATES extension – 2022.

We look forward to feedback or approval of the attached.

Kind regards

s47F

From: s47E(d) @health.gov.au>
Sent: Monday, January 31, 2022 1:35 PM
To: s47F @nps.org.au>
Cc: s47E(d) @health.gov.au>; s22 @health.gov.au>; s22 @health.gov.au>; s47F @nps.org.au>; contracts <contracts@nps.org.au>; NPS MedicineWise Contracts <NPSMedicineWiseContracts@nps.org.au>
Subject: [EXTERNAL] - [SEC=OFFICIAL] FW: Notification of non-grant work: DVA MATES extension - 2022

[WARNING] This message is from an external sender. Please do not click on any links or download any attachments from this email, if you do not trust the sender.

Good afternoon s47F

I refer to the grant notification attached for non-grant work: DVA MATES extension – 2022 which was submitted to the Department on Friday 28 January 2022. The notification as it currently stands cannot be approved by the Department as the work extends beyond the QUM grant agreement end date of 30 June 2022. As such, if you want the Department's approval, can you please arrange for the notification to be redone so that it is only seeking approval from the Department to 30 June 2022. The expected income and net profit will need to be adjusted in line with the shorter time frame. The Department also requires stronger justification in the notification as to why NPS MedicineWise believes there is only a limited degree of cross over with grant funded programs. The information provided does not provide the Department with enough information to determine the accuracy of this statement.

Regards

s22

Department Officer – Quality Use of Medicines

Technology Assessment and Access Division
Pricing & PBS Policy Branch
Australian Government Department of Health
T: 02 6289s22 | E: s22 @health.gov.au
Location: Sirius Building s22
GPO Box 9848, Canberra ACT 2601, Australia

My work days are Monday to Thursday.

The Department of Health acknowledges the Traditional Custodians of Australia and their continued connection to land, sea and community. We pay our respects to all Elders past and present.

From: s47F [redacted] <s47F@nps.org.au>
Sent: Friday, 28 January 2022 8:15 AM
To: s47E(d) [redacted] <[s47E\(d\)@health.gov.au](mailto:s47E(d)@health.gov.au)>
Cc: s47F [redacted] <s47F@nps.org.au>; contracts <contracts@nps.org.au>; NPS MedicineWise Contracts <NPSMedicineWiseContracts@nps.org.au>
Subject: Notification of non-grant work: DVA MATES extension - 2022

REMINDER: Think before you click! This email originated from outside our organisation. Only click links or open attachments if you recognise the sender and know the content is safe.

Dear QUM Team,

Notification of non-grant work: DVA MATES extension – 2022

Please find attached notification **2 of 2** in this batch.

We look forward to feedback or approval of this work.

Kind regards

s47F [redacted]

s47F [redacted]

Business Operations Manager
 Strategy, Programs and Delivery
 Business Operations



Level 7 / 418a Elizabeth St
 Surry Hills NSW 2010
 PO Box 1147
 Strawberry Hills
 NSW 2012

P. (02) 8217 8609
 F. (02) 9211 7578
s47F@nps.org.au
www.nps.org.au

Independent, not-for-profit and evidence based,
 NPS MedicineWise enables better decisions
 about medicines, medical tests and other health
 technologies.



Please consider the environment before printing this email

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."

s22

From: s22 on behalf of s47E(d)
Sent: Friday, 26 August 2022 10:32 AM
To: contracts; s47F @nps.org.au
Cc: s47E(d)
Subject: Notification: Ref# 2022/32C DVA Mates [SEC=OFFICIAL]
Attachments: 2022_32C_DoH Opportunity Submission DVA Mates.pdf

Dear s47F

I refer to NPS MedicineWise Notification Ref#: 2022/32c (DVA Mates) submitted on 9 August 2022.

The Department has approved this notification for the period 1 July 2022 – 31 December 2022 noting NPS MedicineWise's advice that they will not be receiving any additional revenue or net revenue for this period of the approval.

The Department's approval to proceed is only provided for the term of the Grant and does not extend beyond the Program Completion Date, being 31 December 2022.

The Department's approval is given on the basis of the information provided. If there is any material change to the scope of the work, or to the Net Revenue derived from it, please let me know as the Department's approval may need to be reconsidered or qualified.

Regards,

s22

Acting Director, Quality Use of Medicines

Quality Use of Medicines

Technology Assessment and Access Division
 Pricing & PBS Policy Branch
 Australian Government Department of Health and Aged Care
 GPO Box 9848, Canberra ACT 2601, Australia

The Department of Health and Aged Care acknowledges the traditional owners of country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to elders both past and present

s22

From: s47F @nps.org.au>
Sent: Friday, 14 May 2021 2:50 PM
To: s22
Cc: s47E(d); s22; contracts; s47F
Subject: FW: [EXTERNAL] - FW: Notification of non-grant work: DVA Mates [SEC=OFFICIAL]

Categories: s22

REMINDER: Think before you click! This email originated from outside our organisation. Only click links or open attachments if you recognise the sender and know the content is safe.

Dear s22

I refer to the email below.

Would you please be able to:

1. provide a response to the request to reconsider the DVA notification; and
2. confirm whether you intend to respond to the letter from s47F dated 18th November 2020?

Finally, whilst on the subject of notifications, we note the Department has introduced a condition on a number of notification responses time limiting the approvals to 30 June 2022.

As we move ever closer to 30 June 2022 this will become an issue preventing opportunities from proceeding. Accordingly, where an opportunity is notified to the Department in the future that has a proposed end date that extends beyond the Grant period, NPS MedicineWise intends to seek an alternative to a time limiting condition and will make a case for the alternative for the Department's consideration.

I look forward to hearing from you.

Kind regards,

s47F

Business Operations Manager
 Strategy, Programs and Delivery
 Business Operations



Level 7 / 418a Elizabeth St
 Surry Hills NSW 2010
 PO Box 1147
 Strawberry Hills
 NSW 2012

P. (02) 8217 8609
 F. (02) 9211 7578
 s47F @nps.org.au
 www.nps.org.au

Independent, not-for-profit and evidence based,
 NPS MedicineWise enables better decisions
 about medicines, medical tests and other health
 technologies.

Please consider the environment before printing this email

From: s47F
Sent: Monday, February 22, 2021 1:51 PM
To: s22 @health.gov.au>
Cc: s47F @nps.org.au>; s47E(d) @health.gov.au>; contracts
 <contracts@nps.org.au>; s47F @nps.org.au
Subject: RE: [EXTERNAL] - FW: Notification of non-grant work: DVA Mates [SEC=OFFICIAL]

Dear s22

I refer to the email below concerning Notification Ref#: 2020/32 Veterans' MATES - NPS MedicineWise contribution to the module development and planning activities.

NPS MedicineWise seeks reconsideration of the notification taking into account the additional information set out below.

The contributions NPS MedicineWise is contractually required to provide to this project are exclusively from skill and expertise of staff. NPS MedicineWise is not contractually required to contribute any Asset either funded by the Grant or otherwise.

All contract payments to NPS MedicineWise are in return for time spent by staff in advisory roles to assist planning activities and development of content. NPS MedicineWise personnel attend meetings, review papers between meetings and (in normal circumstances) travel. There are no payments associated with the supply of Grant funded assets. Therefore, any Net Revenue that is produced is generated by surplus on revenue from staff effort.

Whilst some Veterans' MATES modules overlap with Grant funded programs, others do not. For example, in 2020/21 NPS MedicineWise will contribute to the planning and publication of various modules by Veterans' Mates including tinnitus. It has no relation to any NPS MedicineWise Grant funded program. However, for that module, the NPS MedicineWise staff contribution involves the same input as any other module.

We acknowledge there can be overlap between a Veterans' MATES module and Grant funded programs, and where this occurs the contribution of NPS MedicineWise made via the skills and experience of staff is possibly more economic. However, any overlap presents an opportunity to ensure messaging in the Veterans' MATES module is consistent with Grant funded messaging. This is consistent with NPS MedicineWise' role as the steward of QUM in Australia and helps Grant funded messaging to reach additional audiences. The project is therefore an opportunity to share Grant funded messaging more widely and to obtain greater return on investment for Grant funded work. At all times this benefit to the Grant is ancillary to the contract deliverables which focus exclusively on NPS MedicineWise providing staff time and expertise.

Addressing the broader discussion concerning principles concerning the Department's decisions to direct NPS MedicineWise Net Revenue, this project is a good example of a non-Grant project which involves NPS MedicineWise staff effort with only ancillary use of Grant funded Assets. In the letter from NPS MedicineWise Deputy CEO to you dated 18 November 2020, we raised the question of what happens to Net Revenue for projects which involve both staff skills and Asset use. We have yet to receive a response to that query. As a result, we remain concerned that the Department may misdirect Net Revenue because, if there are consistent, robust principles being applied to decisions, these are not transparent to NPS MedicineWise.

We therefore ask the Department to consider NPS MedicineWise be permitted to retain 100% of Net Revenue. We also seek a response to the letter dated 18 November 2020.

Please do not hesitate to contact me if further information is required.

Thank you

Kind regards,

s47F

From: s22 <[REDACTED]@health.gov.au> On Behalf Of s47E(d) <[REDACTED]>
 Sent: Friday, October 30, 2020 2:06 PM
 To: s47F <[REDACTED]@nps.org.au>
 Cc: s47E(d) <[REDACTED]@health.gov.au>; s47F <[REDACTED]@nps.org.au>; contracts <contracts@nps.org.au>; NPS MedicineWise Contracts <NPSMedicineWiseContracts@nps.org.au>
 Subject: [EXTERNAL] - FW: Notification of non-grant work: DVA Mates [SEC=OFFICIAL]

[WARNING] This message is from an external sender. Please do not click on any links or download any attachments from this email, if you do not trust the sender.

Dear s47F

I refer to NPS MedicineWise Notification Ref#: 2020/32 Veterans MATES -NPS MedicineWise contribution to the module development and planning activities.

The previous and current grants have funded the development of Therapeutic Programs. As highlighted in the Review of NPS MedicineWise's delivery of the grant, it is critically important that the grant does not cross-subsidise NPS MedicineWise's commercial activities. The Review also highlighted that the MATES Program also implemented similar projects at the same time.

The Department has noted this work as cross-subsidisation of NPS MedicineWise's commercial activities with grant. This work has used at minimum the formative research for the Opioid program funded under the QUM grant which is cross-subsidisation. NPS MedicineWise have also reported that they are engaging with MATES Program on other Therapeutic Programs NPS are responsible for, this includes meetings to develop material on the Heart Failure Program.

Therefore, based on these details the Department does not agree with the statements made in NPS MedicineWise notification regarding that net revenue be retained by NPS. While, the Department notes the contract with Department of Veterans Affairs (DVA) - University of South Australia commenced prior to the current funding agreement coming into effect there is cross subsidisation. Therefore, the Department approves the NPS MedicineWise proposal on the condition that all net revenue attributable to work undertaken be treated as grant funds under Schedule 5 b). NPS MedicineWise will be required to report specifically on this through the financial reporting.

Regards,

s22

Director (Acting), Quality Use of Medicines
Quality Use of Medicines

Technology Assessment and Access Division | Health Resourcing Group

Pricing & PBS Policy Branch

Australian Government Department of Health

s47E(d) [@health.gov.au](mailto:s47E(d)@health.gov.au)

GPO Box 9848, Canberra ACT 2601, Australia

The Department of Health acknowledges the Traditional Custodians of Australia and their continued connection to land, sea and community. We pay our respects to all Elders past and present.

From: s47F [@nps.org.au](mailto:s47F@nps.org.au)>

Sent: Thursday, 15 October 2020 1:16 PM

To: s47E(d) [@health.gov.au](mailto:s47E(d)@health.gov.au)>; s22 [@health.gov.au](mailto:s22@health.gov.au)>; s22 [@health.gov.au](mailto:s22@health.gov.au)>

Cc:

Subject: Notification of non-grant work: DVA Mates

REMINDER : Think before you click! This email originated from outside our organisation. Only click links or open attachments if you recognise the sender and know the content is safe.

Dear QUM Team,

Please find attached notification of non-grant work: PHN Immunisation

This is notification 4 of 5.

We look forward to receiving you feedback.

Kind regards

s47F

Business Operations Manager
Strategy, Programs and Delivery
Business Operations



Level 7 / 418a Elizabeth St
Surry Hills NSW 2010
PO Box 1147
Strawberry Hills
NSW 2012

P (02) 8217 8609
F (02) 9211 7578
s47F [@nps.org.au](mailto:s47F@nps.org.au)
www.nps.org.au

Independent, not-for-profit and evidence based,
NPS MedicineWise enables better decisions
about medicines, medical tests and other health
technologies.



Please consider the environment before printing this email

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."